增强现实通路特异性双眼训练治疗单眼弱视的疗效与安全性(ARPSBT):多中心随机对照试验研究方案
本研究为优势性、多中心、随机对照试验,纳入114例5至55岁单眼弱视患者,按1:1随机分配至双眼训练组或遮盖组,居家治疗每天2小时、共13周。主要结局为弱视眼远距离最佳矫正视力从基线至治疗13周的变化,次要结局包括对比敏感度、远近立体视、眼间抑制、治疗依从性及不良事件发生率。
要点
- 拟纳入114例5至55岁单眼弱视患者,1:1随机分配至双眼训练组或遮盖组。
- 两组均居家治疗每天2小时,持续13周,第2、4、9、13周评估视觉功能。
- 主要结局为弱视眼远距离最佳矫正视力从基线至13周的变化。
核心结论
- 作者假设增强现实通路特异性双眼训练较传统遮盖能显著改善视觉功能,本研究旨在评估该居家双眼治疗对儿童和成人单眼弱视的疗效与安全性。
研究设计与样本
- 优势性、多中心、随机对照试验,纳入114例5至55岁单眼弱视患者,按1:1随机分配至双眼训练组或遮盖组,居家治疗每天2小时、共13周。
- 视觉功能在基线、治疗中期(第2周、第4周、第9周)及治疗结束(第13周)评估。
关键数值与推荐
- 主要结局为弱视眼远距离最佳矫正视力从基线至治疗13周的变化。
- 次要结局包括对比敏感度、远近立体视、眼间抑制、治疗依从性及各次访视的不良事件发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Amblyopia is a common developmental disorder with reduced visual acuity and impairment in binocular functions. Patching the fellow eye, as the gold standard therapy in amblyopia, sometimes fails to achieve satisfactory outcomes because of poor adherence or delayed intervention. Recently, dichoptic/binocular digital therapy in amblyopia has been developed, but no evidence-based binocular treatments with superiority are available. Based on our previous study findings in neural deficits of unilateral amblyopia, we develop a paradigm of pathway-specific visual training using augmented-reality techniques, in which functions of the parvocellular pathway in the amblyopic eye are selectively pushed under binocular viewing. The aim of this trial is to assess the efficacy and safety of this innovative binocular, home-based treatment for children and adults with unilateral amblyopia. We hypothesize that augmented-reality pathway-specific binocular training will significantly improve visual functions compared with traditional patching. METHODS: This is a superiority, multi-center, randomized, controlled trial involving 114 patients, aged between 5 and 55 years, with a diagnosis of unilateral amblyopia. Participants will be randomized 1:1 to either binocular training or patching, and will receive home-based treatment for 2 hours per day over a 13-week period. Their visual functions will be assessed at baseline, mid-treatment (week 2, week 4, week 9), and the end of treatment (week 13). The primary outcome is the change in best-corrected visual acuity at distance in the amblyopic eye from baseline to 13 weeks after treatment. Secondary outcomes include contrast sensitivity, near and far stereoacuity, interocular suppression, treatment adherence, and the incidence of adverse events at each visit. DISCUSSION: This study is the first multi-center randomized controlled trial investigating a home-based augmented-reality binocular therapy targeting neural deficits in children and adults with unilateral amblyopia. We expect that the trial will generate findings that can provide an evidence-based basis for the efficacy and safety of this innovative approach to amblyopia treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06498206. Registered on July 12, 2024.
引用
- Zhou Y, Guo S, Ling L, et al. Efficacy and safety of augmented-reality pathway-specific binocular training in patients with unilateral amblyopia (ARPSBT): study protocol for a multicenter randomized controlled trial. Trials. 2025. PMID: 40598549. doi:10.1186/s13063-025-08927-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。